Aclaris Therapeutics Return on Equity

Aclaris Therapeutics (ACRS) currently reports a ROE of -47.74%. That is below the Healthcare sector average of 13.1%. Use the charts on this page to explore Aclaris Therapeutics's ROE history and peer comparisons.

Aclaris Therapeutics's ROE of -47.74% is lower than the Healthcare sector average of 13.1%. That is roughly 464.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Aclaris Therapeutics's current -47.74% should be judged against Healthcare norms (sector average: 13.1%) and against ACRS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -47.74%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.1%. From there, open related valuation or income-statement pages for Aclaris Therapeutics, and consider following ACRS for alerts when major investors trade the stock.

Aclaris Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -47.74% versus a sector average near 13.1%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ACRS with unrelated industries.